Inventiva S.A. (NASDAQ:IVA - Get Free Report) shares fell 5.2% on Friday . The company traded as low as $2.23 and last traded at $2.27. 5,526 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 22,419 shares. The stock had previously closed at $2.39.
Inventiva Stock Performance
The company has a 50-day simple moving average of $2.50 and a 200-day simple moving average of $3.17.
Institutional Trading of Inventiva
An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,490 shares of the company's stock, valued at approximately $38,000. 19.06% of the stock is owned by institutional investors and hedge funds.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
